103.00 -0.11 (-0.11%)
After hours: 6:45PM EST
|Bid||96.50 x 1000|
|Ask||0.00 x 800|
|Day's Range||102.55 - 106.49|
|52 Week Range||52.17 - 109.05|
|Beta (3Y Monthly)||1.54|
|PE Ratio (TTM)||84.45|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.93|
The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.
ResMed's (RMD) AirFit N30i with a top-of-head connection keeps tubing out of the wearers' way, thus letting them conveniently move and sleep in any position.
# Veeva Systems Inc ### NYSE:VEEV View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for VEEV with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $4.80 billion over the last one-month into ETFs that hold VEEV are among the highest of the last year, but the rate of growth is slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to email@example.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Per the terms of the deal between CVS Health (CVS) and Walmart, the latter will continue to take part in the CVS Caremark PBM commercial and Managed Medicaid retail pharmacy networks.
Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
ServiceNow, Splunk, and Veeva Systems are among 23 stocks expecting 50% to 2,300% Q4 earnings growth.
On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.
Here's how Alger Small Cap Focus Fund (AOFAX) blew away rivals that also focus on small cap stocks.
In a matter of just a few years, "the Cloud" has evolved from a budding new tech feature to one of the main factors driving growth in the technology sector. With this in mind, we've highlighted three stocks that are showing strong cloud-related activity. Check out these three cloud stocks to buy right now!
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
Stock futures: Veeva Systems and Epam Systems entered buy range Wednesday, but in light volume. The market rally needs more top stocks breaking out. Netflix and American Express earnings are on tap.
Veeva Systems (VEEV) closed the most recent trading day at $101.66, moving +0.26% from the previous trading session.
The 8% sell rule is the worst loss an investor should take. The goal is to get out quickly and wait for the stock to become a second chance stock.